HIV Infections Clinical Trial
Official title:
Acu/Moxa for Peripheral Neuropathy in Persons With HIV
This is a sample-size-limited, randomized, blinded (subject and evaluator), sham
acupuncture/placebo moxibustion (sham acu/placebo moxa) controlled clinical trial. The
subjects in this study will be 50 men and women with HIV infection who have a diagnosis of
distal symmetric peripheral neuropathy (DSP). Subjects will be randomized to one of two
experimental intervention conditions:
- Condition 1: subjects receive acu/moxa treatment; and
- Condition 2 (Control Group): subjects receive sham acu/placebo moxa.
All subjects in Conditions 1 and 2 will attend 16 scheduled sessions over 15 weeks, be
administered the same instruments, and submit their daily symptom diaries for analysis. There
will be six weeks of twice weekly treatment sessions, and three follow-up sessions at weeks
9, 11, and 15. All conditions will be identical in duration and be administered by licensed
acupuncturists trained in traditional Chinese medicine (TCM).
Subjects in this early-phase clinical trial will be 50 men and women with HIV infection who
have a diagnosis of Distal Symmetric Peripheral neuropathy (DSP). This study is a
prospective, randomized, sham/placebo controlled, blinded (subject and evaluator), parallel
groups clinical trial. Subjects will be randomized to one of two experimental intervention
conditions:
- Condition 1: subjects receive Acu/Moxa Treatment; and
- Condition 2 (Control Group): subjects receive Sham acupuncture/Placebo moxibustion (Sham
Acu/Placebo Moxa).
Subjects in Conditions 1 and 2 will attend 16 scheduled sessions over 15 weeks. All subjects
will: be blinded/masked to treatment assignments, attend the same number of protocol
sessions, be administered the same instruments, and submit their symptom diaries for data
entry and analysis. After a screening/intake session, randomization and treatment sessions
will follow. There will be six weeks of twice weekly treatment sessions, and three follow-up
sessions at weeks 9, 11 and 15. All conditions will be identical in duration and be
administered by licensed acupuncturists trained in Traditional Chinese Medicine. The aims of
this study include:
1. To establish the feasibility of the combined Acupuncture/Moxibustion treatment for 6
weeks of twice weekly sessions, in order to reduce the pain related to DSP among persons
with HIV/AIDS, and to estimate the effect size of the Acu/Moxa treatment for a future
clinical study. Inclusion of 2-, 4-, and 8-week no-treatment follow-up sessions will
establish the maintainability of benefit.
2. To determine the effect of combined Acupuncture/Moxibustion treatment for 6 weeks of
twice weekly sessions on reducing symptoms of DSP (aching or burning pain, "pins and
needles" sensation, and numbness) among persons with HIV/AIDS.
3. To determine the effect of the combined Acupuncture/Moxibustion treatment for 6 weeks of
twice weekly sessions on patient-perceived DSP symptom improvement and quality of life.
4. To evaluate the logistics of a CAM clinical trial on persons with HIV/AIDS experiencing
DSP.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |